Sermorelin for Recovery: Off-Label Use, Evidence, and Dosing Protocol

What sermorelin is and what it was actually approved for

Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone (GHRH) and the shortest synthetic peptide with GHRH's full biological activity [5]. It is not growth hormone. It acts on the GHRH receptor on pituitary cells and prompts the pituitary to release the body's own growth hormone [5]. In healthy men given an intravenous dose, sermorelin was eliminated quickly, yet growth hormone stayed raised for about 3 hours [6].

Two Geref applications were approved, for two different purposes. NDA 019863, Geref 0.05 mg per ampule, was approved on December 28, 1990 for evaluating the pituitary's ability to secrete growth hormone [1]. NDA 020443, Geref 0.5 mg and 1 mg vials, was approved on September 26, 1997 for treating idiopathic growth hormone deficiency in children with growth failure [1]. Neither approval covered adults, anti-aging, weight loss or athletic performance [1].

The manufacturer discontinued both products in 2008 and asked FDA to withdraw the applications, and FDA withdrew both approvals effective June 18, 2009 [1]. In March 2013 FDA determined that Geref had not been withdrawn from sale for reasons of safety or effectiveness [1]. Sermorelin sold in the US today is compounded, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [8].

Is there evidence sermorelin helps recovery?

A 2026 review of therapeutic peptides in orthopaedics groups sermorelin with growth hormone secretagogues that activate IGF-1 signaling and satellite cell repair, and describes the preclinical results as promising while noting a current lack of clinical trials [4]. A 2026 review in Sports Medicine of peptides marketed for musculoskeletal injury and athletic performance reported that many unapproved peptides show favorable tissue repair results in animal models, but that rigorous human safety data are scarce [9]. A separate 2026 critical review of peptide use in sport concluded that the clinical evidence supporting peptide use in sport is limited, and that most published studies examine therapeutic use under controlled dosing rather than the higher, combined protocols used in bodybuilding [10].

The human studies of sermorelin described below measured growth in children and hormone levels in older men. None measured time to return to sport, healing time or muscle damage markers.

What the human studies actually measured

The largest human experience with sermorelin is in children. In a 1-year, open-label, multicenter study, 110 previously untreated prepubertal children with growth hormone deficiency received GHRH(1-29) 30 micrograms per kg subcutaneously at bedtime; 86 were evaluable [2]. Mean height velocity rose from 4.1 cm per year at baseline to 8.0 cm per year at 6 months and 7.2 cm per year at 12 months, and 74% of the children were good responders at 6 months [2]. A 1999 review of sermorelin in children with idiopathic growth hormone deficiency described the same once-daily bedtime regimen as effective in some prepubertal children, with height-velocity gains sustained over 12 months [5].

In older men, a 1992 randomized study gave 10 healthy men (mean age 68) 0.5 mg and 1 mg of GHRH(1-29) subcutaneously twice daily for 14 days each, in random order, with a 14-day gap between treatments, and compared them with 9 younger men (mean age 26) [3]. At the 1 mg dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the younger men [3]. This was a short physiology study of hormone levels, not a trial of clinical benefit [3].

Dosing: what studies used, and why there is no protocol

No sermorelin product is currently FDA-approved, so there is no current approved dose [1]. The schedules used in published human studies were:

• 30 micrograms per kg once daily, subcutaneously at bedtime, for up to 1 year, in children with growth hormone deficiency [2]
• 0.5 mg or 1 mg subcutaneously twice daily for 14 days in healthy older men [3]

These were used for different research questions, and neither is a recommended dose or a tested recovery protocol [2][3].

Safety

In the 1-year pediatric study, no adverse changes appeared in general biochemistry or hormone tests, fasting glucose did not change, IGF-I was not excessively raised, and sermorelin was well tolerated overall [2]. That is a year of weight-based dosing in children, not a long-term safety record in healthy adults using it for recovery.

A critical review of peptide use in sport raises broader concerns about peptides, including cardiovascular strain, insulin resistance, dyslipidemia and psychiatric instability, but it does not establish the rate or likelihood of these effects with sermorelin [10].

Regulatory status, compounding and sport

Sermorelin does not appear on FDA's page of bulk substances that may present significant safety risks when compounded, in content dated 04/22/2026 [11]. On FDA's list of bulk substances nominated for outsourcing facilities, which are large registered compounders, updated March 21, 2025, sermorelin acetate sits in category 1, under evaluation, and carries the list's mark for substances that are components of FDA-approved drugs [12]. It does not appear in any category on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [13][14].

For anyone competing, sport rules are separate from compounding status. WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, and prohibits it at all times, in and out of competition [7]. It is also named on the 2027 List, in force January 1, 2027 [15].